Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Benzinga · 2d ago
Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.